belimumab


( Last Updated : June 8, 2022)
Generic Name:
belimumab
Project Status:
Pending
Therapeutic Area:
Lupus nephritis
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Benlysta
Project Line:
Reimbursement Review
Project Number:
SR0746-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
In addition to standard therapy for treatment of active lupus nephritis in adult patients.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
In addition to standard therapy for treatment of active lupus nephritis in adult patients.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.